Sema4 Holdings Corp at JPMorgan Healthcare Conference Transcript
Thank you very much for being here on Thursday at the JPMorgan Healthcare Conference. My name is Raji Gunasekaran. I'm an associate on the health care team at JPMorgan. I'm pleased to introduce GeneDx, and we have their President and CEO, Katherine Stueland.
Thank you so much, Raji, and thank you to JPMorgan for hosting us. We've got a great crowd here in San Francisco. It's been a really exciting week for all of us at GeneDx as we've introduced a new company name. We've introduced a new stock ticker WGS, which is really a nod towards our pioneering work in bringing whole genome sequencing to the market to be able to benefit patients.
We also announced that we delivered on 40% revenue growth over the past year and 40% gross margins. We have a clear path to profitability in 2025. So I'm thrilled to be able to be here to share with you what our new vision is as we've brought the best of GeneDx and Sema4 together. First, of course, we will be making forward-looking statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |